A retrospective analysis of incidence and severity of COVID-19 among hypertensive patients: the other side

Clin Exp Hypertens. 2022 Jul 4;44(5):459-463. doi: 10.1080/10641963.2022.2071916. Epub 2022 May 8.

Abstract

Objective: The role of hypertension in COVID-19 has not been clearly elucidated yet. The aim of this study was to evaluate the incidence and severity of COVID-19 in a hypertensive population and assess whether there is a link between blood pressure control and SARS-CoV-2 infection outcomes.

Methods: This was a single-center retrospective observational study that evaluated the incidence and severity of COVID-19 in a chronic hypertensive population (n=1,637) from a specialized consultation of Hypertension and Cardiovascular Risk of Internal Medicine in a tertiary hospital in Madrid (Spain).

Results: A total of 147 COVID-19 patients (9%) were found, with a median age of 59 (±14) years, where 77 (52.4%) patients were male. Forty patients required hospitalization (27.2%), 15 patients had severe COVID-19 (10.2%), and 6 patients died (4.1%). Among the causes of hypertension, 104 (70.7%) patients had essential hypertension and 22 (15%) patients presented primary hyperaldosteronism; and 66 (44.9%) patients presented RH. Severe COVID-19 was associated with age over 65 years (crude OR 4.43 [95% CI 1.3-14.2; p = .012]) and diabetes mellitus (crude OR 4.15 [95% CI 1.3-12.9; p = .014]).

Conclusion: This study showed a lower rate of incidence, hospitalization, and severity of COVID-19 in the hypertensive population.

Keywords: Arterial hypertension; COVID-19; SARS-CoV-2; antihypertensive drugs; prognosis.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • COVID-19* / complications
  • COVID-19* / epidemiology
  • Female
  • Hospitalization
  • Humans
  • Hypertension* / complications
  • Hypertension* / epidemiology
  • Incidence
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • SARS-CoV-2